Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

被引：328
作者：
Ettinger, B
San Martin, J
Crans, G
Pavo, I
机构：
[1] Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2004年 / 19卷 / 05期
关键词：
osteoporosis; parathyroid hormone; bisphosphonates; selective estrogen receptor modulators;
D O I：
10.1359/JBMR.040117
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We investigated the effects of 18 months of treatment with teriparatide in patients previously treated with long-term antiresorptive therapy using bone turnover markers and bone densitometry. Previous raloxifene treatment allowed for teriparatide-induced early bone marker and BMD increases comparable with previously published results for treatment-naive patients. Conversely, previous alendronate treatment reduced the bone marker and BMD response.
引用
收藏
页码：745 / 751
页数：7
相关论文
共 27 条
[1]   The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis [J].
Black, DM ;
Greenspan, SL ;
Ensrud, KE ;
Palermo, L ;
McGowan, JA ;
Lang, TF ;
Garnero, P ;
Bouxsein, ML ;
Bilezikian, JP ;
Rosen, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) :1207-1215
[2]   Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women [J].
Boivin, GY ;
Chavassieux, PM ;
Santora, AC ;
Yates, J ;
Meunier, PJ .
BONE, 2000, 27 (05) :687-694
[3]   Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis [J].
Chavassieux, PM ;
Arlot, ME ;
Reda, C ;
Wei, L ;
Yates, AJ ;
Meunier, PJ .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (06) :1475-1480
[4]   Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal [J].
Cosman, F ;
Nieves, J ;
Woelfert, L ;
Formica, C ;
Gordon, S ;
Shen, V ;
Lindsay, R .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (05) :925-931
[5]   Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women [J].
Cosman, F ;
Nieves, J ;
Woelfert, L ;
Shen, V ;
Lindsay, R .
JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (06) :1051-1055
[6]   Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis:: A paired biopsy study [J].
Dempster, DW ;
Cosman, F ;
Kurland, ES ;
Zhou, H ;
Nieves, J ;
Woelfert, L ;
Shane, E ;
Plavetic, K ;
Müller, R ;
Bilezikian, J ;
Lindsay, R .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (10) :1846-1853
[7]   EVIDENCE THAT INTERMITTENT TREATMENT WITH PARATHYROID-HORMONE INCREASES BONE-FORMATION IN ADULT-RATS BY ACTIVATION OF BONE LINING CELLS [J].
DOBNIG, H ;
TURNER, RT .
ENDOCRINOLOGY, 1995, 136 (08) :3632-3638
[8]   Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -: Results from a 3-year randomized clinical trial [J].
Ettinger, B ;
Black, DM ;
Mitlak, BH ;
Knickerbocker, RK ;
Nickelsen, T ;
Genant, HK ;
Christiansen, C ;
Delmas, PD ;
Zanchetta, JR ;
Stakkestad, J ;
Glüer, CC ;
Krueger, K ;
Cohen, FJ ;
Eckert, S ;
Ensrud, KE ;
Avioli, LV ;
Lips, P ;
Cummings, SR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07) :637-645
[9]   The effects of parathyroid hormone, alendronate, or both in men with osteoporosis [J].
Finkelstein, JS ;
Hayes, A ;
Hunzelman, JL ;
Wyland, JJ ;
Lee, H ;
Neer, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) :1216-1226
[10]   Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34) - A randomized controlled trial [J].
Finkelstein, JS ;
Klibanski, A ;
Arnold, AL ;
Toth, TL ;
Hornstein, MD ;
Neer, RM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (12) :1067-1073
123